An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.
<h4>Background</h4>A major challenge in oncology is the selection of the most effective chemotherapeutic agents for individual patients, while the administration of ineffective chemotherapy increases mortality and decreases quality of life in cancer patients. This emphasizes the need to...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1a97258ca2ae40838cd91ac9f1ac4537 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1a97258ca2ae40838cd91ac9f1ac4537 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1a97258ca2ae40838cd91ac9f1ac45372021-11-25T06:12:54ZAn integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.1932-620310.1371/journal.pone.0001908https://doaj.org/article/1a97258ca2ae40838cd91ac9f1ac45372008-04-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18382681/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>A major challenge in oncology is the selection of the most effective chemotherapeutic agents for individual patients, while the administration of ineffective chemotherapy increases mortality and decreases quality of life in cancer patients. This emphasizes the need to evaluate every patient's probability of responding to each chemotherapeutic agent and limiting the agents used to those most likely to be effective.<h4>Methods and results</h4>Using gene expression data on the NCI-60 and corresponding drug sensitivity, mRNA and microRNA profiles were developed representing sensitivity to individual chemotherapeutic agents. The mRNA signatures were tested in an independent cohort of 133 breast cancer patients treated with the TFAC (paclitaxel, 5-fluorouracil, adriamycin, and cyclophosphamide) chemotherapy regimen. To further dissect the biology of resistance, we applied signatures of oncogenic pathway activation and performed hierarchical clustering. We then used mRNA signatures of chemotherapy sensitivity to identify alternative therapeutics for patients resistant to TFAC. Profiles from mRNA and microRNA expression data represent distinct biologic mechanisms of resistance to common cytotoxic agents. The individual mRNA signatures were validated in an independent dataset of breast tumors (P = 0.002, NPV = 82%). When the accuracy of the signatures was analyzed based on molecular variables, the predictive ability was found to be greater in basal-like than non basal-like patients (P = 0.03 and P = 0.06). Samples from patients with co-activated Myc and E2F represented the cohort with the lowest percentage (8%) of responders. Using mRNA signatures of sensitivity to other cytotoxic agents, we predict that TFAC non-responders are more likely to be sensitive to docetaxel (P = 0.04), representing a viable alternative therapy.<h4>Conclusions</h4>Our results suggest that the optimal strategy for chemotherapy sensitivity prediction integrates molecular variables such as ER and HER2 status with corresponding microRNA and mRNA expression profiles. Importantly, we also present evidence to support the concept that analysis of molecular variables can present a rational strategy to identifying alternative therapeutic opportunities.Kelly H SalterChaitanya R AcharyaKelli S WaltersRichard RedmanAriel AnguianoKatherine S GarmanCarey K AndersSayan MukherjeeHolly K DressmanWilliam T BarryKelly P MarcomJohn OlsonJoseph R NevinsAnil PottiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 3, Iss 4, p e1908 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Kelly H Salter Chaitanya R Acharya Kelli S Walters Richard Redman Ariel Anguiano Katherine S Garman Carey K Anders Sayan Mukherjee Holly K Dressman William T Barry Kelly P Marcom John Olson Joseph R Nevins Anil Potti An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. |
| description |
<h4>Background</h4>A major challenge in oncology is the selection of the most effective chemotherapeutic agents for individual patients, while the administration of ineffective chemotherapy increases mortality and decreases quality of life in cancer patients. This emphasizes the need to evaluate every patient's probability of responding to each chemotherapeutic agent and limiting the agents used to those most likely to be effective.<h4>Methods and results</h4>Using gene expression data on the NCI-60 and corresponding drug sensitivity, mRNA and microRNA profiles were developed representing sensitivity to individual chemotherapeutic agents. The mRNA signatures were tested in an independent cohort of 133 breast cancer patients treated with the TFAC (paclitaxel, 5-fluorouracil, adriamycin, and cyclophosphamide) chemotherapy regimen. To further dissect the biology of resistance, we applied signatures of oncogenic pathway activation and performed hierarchical clustering. We then used mRNA signatures of chemotherapy sensitivity to identify alternative therapeutics for patients resistant to TFAC. Profiles from mRNA and microRNA expression data represent distinct biologic mechanisms of resistance to common cytotoxic agents. The individual mRNA signatures were validated in an independent dataset of breast tumors (P = 0.002, NPV = 82%). When the accuracy of the signatures was analyzed based on molecular variables, the predictive ability was found to be greater in basal-like than non basal-like patients (P = 0.03 and P = 0.06). Samples from patients with co-activated Myc and E2F represented the cohort with the lowest percentage (8%) of responders. Using mRNA signatures of sensitivity to other cytotoxic agents, we predict that TFAC non-responders are more likely to be sensitive to docetaxel (P = 0.04), representing a viable alternative therapy.<h4>Conclusions</h4>Our results suggest that the optimal strategy for chemotherapy sensitivity prediction integrates molecular variables such as ER and HER2 status with corresponding microRNA and mRNA expression profiles. Importantly, we also present evidence to support the concept that analysis of molecular variables can present a rational strategy to identifying alternative therapeutic opportunities. |
| format |
article |
| author |
Kelly H Salter Chaitanya R Acharya Kelli S Walters Richard Redman Ariel Anguiano Katherine S Garman Carey K Anders Sayan Mukherjee Holly K Dressman William T Barry Kelly P Marcom John Olson Joseph R Nevins Anil Potti |
| author_facet |
Kelly H Salter Chaitanya R Acharya Kelli S Walters Richard Redman Ariel Anguiano Katherine S Garman Carey K Anders Sayan Mukherjee Holly K Dressman William T Barry Kelly P Marcom John Olson Joseph R Nevins Anil Potti |
| author_sort |
Kelly H Salter |
| title |
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. |
| title_short |
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. |
| title_full |
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. |
| title_fullStr |
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. |
| title_full_unstemmed |
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. |
| title_sort |
integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2008 |
| url |
https://doaj.org/article/1a97258ca2ae40838cd91ac9f1ac4537 |
| work_keys_str_mv |
AT kellyhsalter anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT chaitanyaracharya anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT kelliswalters anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT richardredman anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT arielanguiano anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT katherinesgarman anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT careykanders anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT sayanmukherjee anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT hollykdressman anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT williamtbarry anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT kellypmarcom anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT johnolson anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT josephrnevins anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT anilpotti anintegratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT kellyhsalter integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT chaitanyaracharya integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT kelliswalters integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT richardredman integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT arielanguiano integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT katherinesgarman integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT careykanders integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT sayanmukherjee integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT hollykdressman integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT williamtbarry integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT kellypmarcom integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT johnolson integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT josephrnevins integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer AT anilpotti integratedapproachtothepredictionofchemotherapeuticresponseinpatientswithbreastcancer |
| _version_ |
1718414028465766400 |